<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480230</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2017-0467</org_study_id>
    <secondary_id>MS100070_0020</secondary_id>
    <nct_id>NCT03480230</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arafat Tfayli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the response rate to neoadjuvant Compound 121564 plus
      platinum doublet chemotherapy in patients with early stage non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, single-arm multi-center phase II trial of neoadjuvant Compound 121564 plus
      platinum doublet chemotherapy conducted among patients with early stage (IB, II, IIIA)
      non-small cell lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>At week 9</time_frame>
    <description>To assess the overall response rate (ORR) of patients receiving neoadjuvant Compound 121564 plus platinum doublet chemotherapy based on RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>To assess the pathologic complete response rate in patients receiving combination Compound 121564 and chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathologic response rate (&lt;10% viable tumor cells)</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>To assess the major pathologic response rate (&lt;10% viable tumor cells) in patients receiving combination Compound 121564 and chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>At 1, 2 and 3 years</time_frame>
    <description>To assess progression-free survival (PFS) at 1, 2 and 3 years in patients receiving a combination of Compound 121564 plus platinum doublet chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At 1, 2 and 3 years</time_frame>
    <description>To assess overall survival (OS) in patients receiving a combination of Compound 121564 plus platinum doublet chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria in enrolled squamous vs. non-squamous lung cancer patients</measure>
    <time_frame>At week 9</time_frame>
    <description>To compare the ORR in enrolled squamous vs. non-squamous lung cancer patients receiving the proposed treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in enrolled squamous vs. non-squamous lung cancer patients</measure>
    <time_frame>At 1, 2 and 3 years</time_frame>
    <description>To compare the PFS in enrolled squamous vs. non-squamous lung cancer patients receiving the proposed treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in enrolled squamous vs. non-squamous lung cancer patients</measure>
    <time_frame>At 1, 2 and 3 years</time_frame>
    <description>To compare the OS in enrolled squamous vs. non-squamous lung cancer patients receiving the proposed treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-related outcomes Quality of Life assessment using the questionnaire for functional assessment of cancer therapy for patients with lung cancer (FACT-L version 4)</measure>
    <time_frame>At week 9</time_frame>
    <description>To assess patient-related outcomes in patients receiving a combination of Compound 121564 plus platinum doublet chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v 4.0</measure>
    <time_frame>With every administration</time_frame>
    <description>To assess the tolerability of the proposed treatment regimen in the cohort of patient enrolled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1</measure>
    <time_frame>At week 9</time_frame>
    <description>To analyze as exploratory analysis the ORR in patients with 50% or more PD-L1 expression level vs. patients with less than 50% PD-L1 expression level receiving the proposed treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1</measure>
    <time_frame>At 1, 2 and 3 years</time_frame>
    <description>To analyze as exploratory analysis the PFS in patients with 50% or more PD-L1 expression level vs. patients with less than 50% PD-L1 expression level receiving the proposed treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1</measure>
    <time_frame>At 1, 2 and 3 years</time_frame>
    <description>To analyze as exploratory analysis the OS in patients with 50% or more PD-L1 expression level vs. patients with less than 50% PD-L1 expression level receiving the proposed treatment regimen.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Small Cell Lung Cancer Stage</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-squamous histology:
Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.
Compound 565994 500 mg/m2 administered over 10 minutes, and
Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.
Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.
Squamous histology:
Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.
Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.
Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.
Platinum and Compound 343782 will be given for 3 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound 121564</intervention_name>
    <description>Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females aged ≥ 18 years.

          2. Histologically confirmed NSCLC (squamous and non-squamous).

          3. High-risk stage IB (tumor ≥ 4 cm in size, or grade 3, or with visceral pleura
             involvement), II or IIIA disease.

          4. Have biopsy tissue available (fresh and archived) for PD-L1 and correlative studies
             testing prior to therapy.

          5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤

        1. 6) Have a life expectancy of ≥ 6 months. 7) No previous systemic anticancer therapy or
        surgical resection for his or her NSCLC. 8) Subject has voluntarily agreed to participate
        by giving written informed consent for the trial. 9) Subject must be willing and able to
        comply with scheduled visits, treatment schedule and laboratory testing. 10) Female
        subjects of childbearing potential must have a negative urine or serum pregnancy test
        within 24 hours prior to receiving the first dose of study medication. 11) Females should
        not be breastfeeding. 12) Female subjects of childbearing potential as well as males
        sexually active with women of childbearing potential must be willing to use an adequate
        method of contraception. 13) Have pulmonary and cardiac function testing deemed adequate
        for thoracic surgical intervention. 14) Have adequate organ function by meeting the
        following:

          1. Absolute neutrophil count (ANC) ≥1,500/mcL.

          2. Platelets ≥100,000/mcL.

          3. Hemoglobin ≥9 g/dL.

          4. Serum creatinine ≤1.5 X upper limit of normal (ULN) OR calculated creatinine clearance
             (CrCl) (GFR can also be used in place of creatinine or CrCl) ≥60 mL/min for subjects
             with creatinine levels &gt; 1.5 X institutional ULN.

          5. Serum total bilirubin ≤ ULN.

          6. AST (SGOT) and ALT (SGPT) ≤ 1.5 X ULN.

          7. Alkaline phosphatase ≤ 2.5 X ULN.

          8. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless the
             subject is receiving anticoagulant therapy.

          9. Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless the subject is
             receiving anticoagulant therapy.

        Exclusion Criteria:

          1. Subject deemed unfit for surgery (by pulmonary or cardiac assessment).

          2. Subject with known autoimmune disease that has required systemic therapy in the last 2
             years.

          3. Prior organ transplantation including allogenic stem-cell transplantation.

          4. Clinically significant (i.e. active) cardiovascular disease: cerebral vascular
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months
             prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart
             Association Classification Class II), or serious cardiac arrhythmia requiring
             medication.

          5. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade &gt; 1); however,
             alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety
             risk based on investigator's judgment are acceptable.

          6. Subject on immunosuppressive therapy or corticosteroids within 14 days prior to
             starting study drugs.

          7. Subject with interstitial lung disease that is symptomatic or history of pneumonitis
             that required oral or systemic glucocorticoids to manage.

          8. Subject must have recovered from the effects of major surgery or significant trauma at
             least 14 days prior to therapy.

          9. Subject with previous malignancies are excluded unless complete remission was achieved
             at least 2 years prior to therapy.

         10. Other active malignancy requiring concurrent intervention.

         11. Subject with active infection requiring systemic therapy.

         12. Subject with known history of testing positive for human immunodeficiency virus (HIV)
             or known to have acquired immunodeficiency syndrome (AIDS).

         13. Subject has known active hepatitis B or C.

         14. Vaccination within 4 weeks of the first dose of Compound 121564 and while on trials is
             prohibited except for administration of inactivated vaccines.

         15. Subject is pregnant or breastfeeding.

         16. Subject has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         17. Subject previously had a severe hypersensitivity reaction to any of the study drugs.

         18. Subject is currently participating and receiving study therapy from another clinical
             trial.

         19. Subject had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an
             antibody targeting other immuno-regulatory receptors or mechanisms.

         20. Patient who is not willing to sign the consent form.

         21. Legal incapacity or limited legal capacity patients receiving other oncology specific
             medication not authorized in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arafat H Tfayli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arafat H Tfayli, MD</last_name>
    <phone>+961 1 350 000</phone>
    <phone_ext>7986</phone_ext>
    <email>at35@aub.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taher Abu-Hejleh, MD</last_name>
      <phone>+962 6 53 00 460</phone>
      <email>ta.11703@khcc.jo</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arafat H Tfayli, MD</last_name>
      <phone>+961 1 350 000</phone>
      <phone_ext>7986</phone_ext>
      <email>at35@aub.edu.lb</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellevue Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fadi Karak, MD</last_name>
      <phone>+961 1 682 666</phone>
      <phone_ext>5620</phone_ext>
      <email>elkarak@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lebanese American University Medical Center-Rizk Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hady Ghanem, MD</last_name>
      <phone>+961 76 477 647</phone>
      <phone_ext>5414</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammoud Hospital University Medical Center</name>
      <address>
        <city>Sidon</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fadi Farhat, MD</last_name>
      <phone>+961 7 723 111</phone>
      <phone_ext>1141</phone_ext>
      <email>drfadi.clinic@gmail.com; drfadi.research@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Arafat Tfayli</investigator_full_name>
    <investigator_title>Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Platinum doublet chemotherapy</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

